Journal article icon

Journal article

Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial

Abstract:

To evaluate tumour necrosis factor inhibitor (TNFi) drug-levels and presence of anti-drug antibodies (ADAb) in patients with inflammatory arthritis who taper TNFi compared to TNFi continuation. Patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis on stable TNFi dose and in low disease activity ≥ 12 months were randomised (2:1) to disease activity-guided tapering or control. Blood samples at baseline, 12- and 18-months were evaluated for TNFi drug-levels and ADAb...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1007/s00296-024-05665-7

Authors


Publisher:
Springer
Journal:
Rheumatology International More from this journal
Publication date:
2024-07-24
Acceptance date:
2024-07-10
DOI:
EISSN:
1437-160X
ISSN:
0172-8172
Language:
English
Keywords:
Pubs id:
2016181
Local pid:
pubs:2016181
Deposit date:
2024-07-17

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP